Long-term Management of Homozygous Protein C Deficiency: Replacement Therapy with Subcutaneous Purified Protein C Concentrate
César Sanz-Rodrı́guez(Merck Biopharma Co., Ltd. (Japan)), N. Gómez Gómez(Spanish Society of Hematology and Hemotherapy), Pedro Zapater(Hospital Universitario de La Princesa), Enrique Granados(Spanish Society of Hematology and Hemotherapy), Inmaculada Pinilla(Spanish Society of Hematology and Hemotherapy), V. Gómez-G. de Soria(Spanish Society of Hematology and Hemotherapy), Juan José Gil‐Fernández(Spanish Society of Hematology and Hemotherapy), J.M. Fernández-Rañada(Spanish Society of Hematology and Hemotherapy), Núria Sala(Inserm)
Cited by 47
Related Papers
Vorinostat in solid and hematologic malignancies
|Journal of Hematology & Oncology|2009|204
Chronic depolarization prevents programmed death of sympathetic neurons in vitro but does not support growth: requirement for Ca2+ influx but not Trk activation
|Journal of Neuroscience|1995|170
Primary hepatic lymphoma
|Cancer|2001|157
Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: a prospective observational study
|Critical Care|2006|128
Evaluation of the Long-Term Tolerability and Clinical Benefit of Vorinostat in Patients With Advanced Cutaneous T-Cell Lymphoma
|Clinical Lymphoma & Myeloma|2009|97